Halozyme (HALO) Stock Forecast & Price Target

Compare

1,124 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HALO Analyst Ratings

Moderate Buy

5 Buy

2 Hold

1 Sell

Based on 8 analysts giving stock ratings to

Halozyme

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HALO Stock 12 Month Forecast

Average Price Target

$77.63

▲(24.79% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Halozyme in the last 3 months. The average price target is $77.63 with a high forecast of $92.00 and a low forecast of $56.00. The average price target represents a 24.79% change from the last price of $62.21.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"46":"$46","93":"$93","57.75":"$57.8","69.5":"$69.5","81.25":"$81.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":92,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$92.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":77.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$77.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$56.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[46,57.75,69.5,81.25,93],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.1,69.93846153846154,71.77692307692307,73.61538461538461,75.45384615384614,77.29230769230769,79.13076923076923,80.96923076923076,82.8076923076923,84.64615384615385,86.48461538461538,88.32307692307693,90.16153846153846,{"y":92,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.1,68.83307692307692,69.56615384615384,70.29923076923076,71.03230769230768,71.7653846153846,72.49846153846153,73.23153846153846,73.96461538461539,74.69769230769231,75.43076923076923,76.16384615384615,76.89692307692307,{"y":77.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,68.1,67.16923076923077,66.23846153846154,65.3076923076923,64.37692307692308,63.44615384615384,62.51538461538461,61.58461538461538,60.65384615384615,59.72307692307692,58.79230769230769,57.86153846153846,56.93076923076923,{"y":56,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.81,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.64,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.87,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.92,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$92.00

Average Price Target$77.63

Lowest Price Target$56.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Brendan Smith

TD Cowen

$79

Buy

26.99%

Upside

Reiterated

12/05/25

Analysts Offer Insights on Healthcare Companies: MapLight Therapeutics, Inc. (NASDAQ: MPLT) and Halozyme (NASDAQ: HALO)We expect '26 to be another year of outsized revenue growth w/ minimal headline/downside risk at these levels.

Corinne Johnson

Goldman Sachs

$56

Sell

-9.98%

Downside

Downgraded

12/04/25

Halozyme downgraded to Sell from Neutral at Goldman SachsHalozyme downgraded to Sell from Neutral at Goldman Sachs

Mitchell Kapoor

H.C. Wainwright

$90

Buy

44.67%

Upside

Reiterated

11/28/25

Strategic Acquisition and FDA Approval Bolster Halozyme's Market Position with a Buy Rating

Jason Butler

Citizens JMP

$91→$92

Buy

47.89%

Upside

Reiterated

11/04/25

Halozyme price target raised to $92 from $91 at Citizens JMPHalozyme price target raised to $92 from $91 at Citizens JMP

Sean Laaman

Morgan Stanley

$79

Buy

26.99%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Halozyme (NASDAQ: HALO) and Progyny (NASDAQ: PGNY)

Jessica Fye

J.P. Morgan

$63→$65

Hold

4.48%

Upside

Reiterated

10/27/25

Halozyme price target raised to $65 from $63 at JPMorganHalozyme price target raised to $65 from $63 at JPMorgan

David Risinger

Leerink Partners

$70

Hold

12.52%

Upside

Upgraded

10/16/25

Halozyme upgraded to Market Perform from Underperform at LeerinkHalozyme upgraded to Market Perform from Underperform at Leerink

Robert Wasserman

Benchmark Co.

$75→$90

Buy

44.67%

Upside

Reiterated

09/24/25

Halozyme's Strong Financial Performance and Strategic Positioning Justify Buy Rating Amid Patent ChallengesWe continue to rate HALO shares a Buy, and our $90 price target is based on 8.5x estimated 2025E revenues and represents roughly 15% potential share price appreciation from current levels.

Mohit Bansal

Wells Fargo

$65

Hold

4.48%

Upside

Reiterated

06/02/25

We rate HALO Equal Weight as we believe the value of the company's current partnerships and anticipated new launches are in the name.

Michael DiFiore

Evercore ISI

$55

Buy

-11.59%

Downside

Reiterated

05/15/25

Evercore ISI reiterates Outperform Rating on Halozyme Therapeutics (HALO)Evercore ISI analyst Michael DiFiore reiterated an Outperform rating on Halozyme Therapeutics (NASDAQ: HALO).

Joseph Catanzaro

Mizuho Securities

$53

Hold

-14.80%

Downside

Reiterated

03/06/25

Piper Sandler Keeps Their Hold Rating on Halozyme (HALO)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Brendan Smith

TD Cowen

$79

Buy

26.99%

Upside

Reiterated

12/05/25

Corinne Johnson

Goldman Sachs

$56

Sell

-9.98%

Downside

Downgraded

12/04/25

Halozyme downgraded to Sell from Neutral at Goldman SachsHalozyme downgraded to Sell from Neutral at Goldman Sachs

Mitchell Kapoor

H.C. Wainwright

$90

Buy

44.67%

Upside

Reiterated

11/28/25

Strategic Acquisition and FDA Approval Bolster Halozyme's Market Position with a Buy Rating

Jason Butler

Citizens JMP

$91→$92

Buy

47.89%

Upside

Reiterated

11/04/25

Halozyme price target raised to $92 from $91 at Citizens JMPHalozyme price target raised to $92 from $91 at Citizens JMP

Sean Laaman

Morgan Stanley

$79

Buy

26.99%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (NASDAQ: ALLO), Halozyme (NASDAQ: HALO) and Progyny (NASDAQ: PGNY)

Jessica Fye

J.P. Morgan

$63→$65

Hold

4.48%

Upside

Reiterated

10/27/25

Halozyme price target raised to $65 from $63 at JPMorganHalozyme price target raised to $65 from $63 at JPMorgan

David Risinger

Leerink Partners

$70

Hold

12.52%

Upside

Upgraded

10/16/25

Halozyme upgraded to Market Perform from Underperform at LeerinkHalozyme upgraded to Market Perform from Underperform at Leerink

Robert Wasserman

Benchmark Co.

$75→$90

Buy

44.67%

Upside

Reiterated

09/24/25

Mohit Bansal

Wells Fargo

$65

Hold

4.48%

Upside

Reiterated

06/02/25

We rate HALO Equal Weight as we believe the value of the company's current partnerships and anticipated new launches are in the name.

Michael DiFiore

Evercore ISI

$55

Buy

-11.59%

Downside

Reiterated

05/15/25

Evercore ISI reiterates Outperform Rating on Halozyme Therapeutics (HALO)Evercore ISI analyst Michael DiFiore reiterated an Outperform rating on Halozyme Therapeutics (NASDAQ: HALO).

Joseph Catanzaro

Mizuho Securities

$53

Hold

-14.80%

Downside

Reiterated

03/06/25

Piper Sandler Keeps Their Hold Rating on Halozyme (HALO)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Halozyme

1 Month

xxx

Success Rate

17/29 ratings generated profit

Average Return

+3.14%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 58.62% of your transactions generating a profit, with an average return of +3.14% per trade.

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+6.05%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +6.05% per trade.

1 Year

Mitchell KapoorH.C. Wainwright

Success Rate

22/26 ratings generated profit

Average Return

+20.77%

reiterated a buy rating 17 days ago

Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +20.77% per trade.

2 Years

xxx

Success Rate

25/29 ratings generated profit

Average Return

+26.19%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 86.21% of your transactions generating a profit, with an average return of +26.19% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HALO Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HALO has received 18 Buy Ratings, 3 Hold Ratings, and 2 Sell Ratings. HALO average Analyst price target in the past 3 months is 77.63.

Each month's total comprises the sum of three months' worth of ratings.

HALO Financial Forecast

HALO Earnings Forecast

Next quarter’s earnings estimate for HALO is $1.90 with a range of $1.82 to $2.03. The previous quarter’s EPS was $1.72. HALO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year HALO has Performed in-line its overall industry.

HALO Sales Forecast

Next quarter’s sales forecast for HALO is $393.92M with a range of $373.10M to $417.00M. The previous quarter’s sales results were $354.26M. HALO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year HALO has Performed in-line its overall industry.

HALO Stock Forecast FAQ

What is HALO’s average 12-month price target, according to analysts?

Based on analyst ratings, Halozyme Therapeutics’s 12-month average price target is 77.63.

What is HALO’s upside potential, based on the analysts’ average price target?

Halozyme Therapeutics has 24.79% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HALO a Buy, Sell or Hold?

Halozyme Therapeutics has a consensus rating of Moderate Buy which is based on 5 buy ratings, 2 hold ratings and 1 sell ratings.

What is Halozyme Therapeutics’s price target?

The average price target for Halozyme Therapeutics is 77.63. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $92.00 ,the lowest forecast is $56.00. The average price target represents 24.79% Increase from the current price of $62.21.

What do analysts say about Halozyme Therapeutics?

Halozyme Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of HALO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Halozyme (HALO) Stock Forecast & Price Target

HALO Analyst Ratings

HALO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Halozyme

HALO Analyst Recommendation Trends

HALO Financial Forecast

HALO Earnings Forecast

HALO Sales Forecast

HALO Stock Forecast FAQ

Detailed List of Analyst Forecasts